Overview Financials News + Filings Key Docs Charts Holdings Ownership Insiders
|
|
GENOMIC HEALTH INC (GHDX)
|
Add to portfolio |
|
|
|
| Price: |
$63.44
| | Metrics |
| OS: |
37.6
|
M
| |
14
|
% ROE
|
| Market cap: |
$2.38
|
B
| |
16
|
% ROIC
|
|
Net cash:
|
$275
|
M
| |
$7.33
|
per share
|
|
EV:
|
$2.11
|
B
| | | |
| | | | | |
| TTM Valuation | | | |
|
EBITDA
|
$68.7
|
M
| |
30.7
|
x EV/EBITDA
|
|
EBIT
|
$55.5
|
M
| |
38.0
|
x EV/EBIT
|
| EPS |
$1.47
| |
43.2
|
x P/E
|
|
|
| |
|
|
|
Recent News + Filings (All items)
|
Revenue Mix by Segment
|
Financial Summary (All financials)
| In millions, except per share items | Dec-31-18 | Dec-31-17 | Dec-31-16 | Dec-31-15 | Dec-31-14 | Dec-31-13 | Dec-31-12 | Dec-31-11 |
| Revenues | 394.1 | 340.8 | 327.9 | 287.5 | 275.7 | 261.6 | 235.2 | 206.1 |
| Revenue growth | 15.7% | 3.9% | 14.1% | 4.3% | 5.4% | 11.2% | 14.1% | 15.7% |
| Cost of goods sold | 64.3 | 54.7 | 58.8 | 55.1 | 48.7 | 42.1 | 37.0 | 33.8 |
| Gross profit | 329.8 | 286.0 | 269.0 | 232.3 | 227.0 | 219.5 | 198.2 | 172.3 |
| Gross margin | 83.7% | 83.9% | 82.1% | 80.8% | 82.3% | 83.9% | 84.3% | 83.6% |
| Sales and marketing | 164.8 | 157.0 | 151.0 | 143.6 | 137.8 | 112.8 | 93.6 | 83.6 |
| Research and development | 64.2 | 62.8 | 60.2 | 58.4 | 53.1 | 64.2 | 49.1 | 39.9 |
| General and administrative | 76.9 | 72.7 | 73.3 | 64.3 | 59.7 | 54.4 | 47.1 | 40.5 |
| EBIT | 23.9 | -6.5 | -15.4 | -34.0 | -23.6 | -11.8 | 8.4 | 8.3 |
| EBIT margin | 6.1% | -1.9% | -4.7% | -11.8% | -8.6% | -4.5% | 3.6% | 4.0% |
| Pre-tax income | 26.9 | -2.4 | -12.5 | -34.3 | -24.2 | -12.4 | 8.7 | 8.3 |
| Income taxes | 1.2 | 1.5 | 1.4 | -1.0 | 0.4 | 0.3 | 0.4 | 0.4 |
| Tax rate | 4.6% | | | 2.9% | | | 4.9% | 5.2% |
| Net income | 25.7 | -3.9 | -13.9 | -33.3 | -24.6 | -12.8 | 8.2 | 7.8 |
| Net margin | 6.5% | -1.1% | -4.2% | -11.6% | -8.9% | -4.9% | 3.5% | 3.8% |
| |
| Diluted EPS | $0.68 | ($0.11) | ($0.42) | ($1.03) | ($0.78) | ($0.42) | $0.26 | $0.26 |
| Shares outstanding (diluted) | 37.6 | 34.5 | 33.3 | 32.4 | 31.5 | 30.5 | 32.2 | 30.8 |
| |
| EBIT is a non-GAAP figure that excludes all non-recurring expenses: restructuring costs, asset impairments, IPR&D writeoffs, and other unusual charges. |
|
|